Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 397421, 6 pages
http://dx.doi.org/10.1155/2014/397421
Research Article

Effects of Various Antibiotics Alone or in Combination with Doripenem against Klebsiella pneumoniae Strains Isolated in an Intensive Care Unit

1Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Beyazit, 34116 Istanbul, Turkey
2Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Istanbul Medipol, 34083 Istanbul, Turkey

Received 4 July 2014; Accepted 1 September 2014; Published 28 October 2014

Academic Editor: Abdelwahab Omri

Copyright © 2014 Berna Ozbek Celik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Podschun and U. Ullmann, “Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors,” Clinical Microbiology Reviews, vol. 11, no. 4, pp. 589–603, 1998. View at Google Scholar · View at Scopus
  2. A. Asensio, A. Oliver, P. González-Diego et al., “Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection,” Clinical Infectious Diseases, vol. 30, no. 1, pp. 55–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Akova, G. L. Daikos, L. Tzouvelekis, and Y. Carmeli, “Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria,” Clinical Microbiology and Infection, vol. 18, no. 5, pp. 439–448, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. Z. Deris, H. H. Yu, K. Davis et al., “The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model,” Antimicrobial Agents and Chemotherapy, vol. 56, pp. 5103–5112, 2012. View at Publisher · View at Google Scholar
  5. J. A. Korvick, C. S. Bryan, B. Farber et al., “Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy,” Antimicrobial Agents and Chemotherapy, vol. 36, no. 12, pp. 2639–2644, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Elemam, J. Rahimian, and M. Doymaz, “In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae,” Journal of Clinical Microbiology, vol. 48, no. 10, pp. 3558–3562, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. G. Jernigan, E. G. Press, M. H. Nguyen, C. J. Clancy, and R. K. Shields, “The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 6, pp. 3395–3398, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Kadar, B. Kocsis, A. Toth, and et al, “Synergistic antibiotic combinations for colistin-resistant Klebsiella pneumoniae,” Acta Microbiologica et Immunologica Hungarica, vol. 60, no. 2, pp. 201–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Le, B. McKee, W. Srisupha-Olarn, and D. S. Burgess, “In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae,” Journal of Clinical Medicine Research, vol. 3, pp. 101–110, 2011. View at Google Scholar
  10. S. Pournaras, G. Vrioni, E. Neou et al., “Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay,” International Journal of Antimicrobial Agents, vol. 37, no. 3, pp. 244–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Urban, N. Mariano, and J. J. Rahal, “In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2732–2734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P.-Y. Lee, W.-N. Chang, C.-H. Lu et al., “Clinical features and in vitro antimicrobial susceptibilities of community-acquired Klebsiella pneumoniae meningitis in Taiwan,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 4, pp. 957–962, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Patel, S. Huprikar, S. H. Factor, S. G. Jenkins, and D. P. Calfee, “Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies,” Infection Control and Hospital Epidemiology, vol. 29, no. 12, pp. 1099–1106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. W. Bundtzen, A. U. Gerber, D. L. Cohn, and W. A. Craig, “Postantibiotic suppression of bacterial growth,” Reviews of Infectious Diseases, vol. 3, no. 1, pp. 28–37, 1981. View at Publisher · View at Google Scholar · View at Scopus
  15. W. A. Craig and S. Gudmundsson, “The postantibiotic effect,” in Antibiotics in Laboratory Medicine, V. Lorian, Ed., pp. 296–329, Williams and Wilkins, Baltimore, Md, USA, 4th edition, 1996. View at Google Scholar
  16. P. J. MacDonald, W. A. Craig, and C. M. Kunin, “Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time,” Journal of Infectious Diseases, vol. 135, no. 2, pp. 217–223, 1977. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Spivey, “The postantibiotic effect,” Clinical Pharmacy, vol. 11, no. 10, pp. 865–875, 1992. View at Google Scholar · View at Scopus
  18. W. A. Craig, “The role of pharmacodynamics in effective treatment of community-acquired pathogens,” Advanced Studies in Medicine, vol. 2, pp. 126–134, 2002. View at Google Scholar
  19. Clinical and Laboratory Standards Institute (CLSI), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard M7-A7, CLSI, Wayne, Ill, USA, 7th edition, 2006.
  20. R. Hope, M. Warner, S. Mushtaq, M. E. Ward, T. Parsons, and D. M. Livermore, “Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 6, pp. 1042–1046, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. K. Pillai, R. C. Moellering Jr., and G. M. Eliopoulos, “Antimicrobial combinations,” in Antibiotics in Laboratory Medicine, V. Lorian, Ed., pp. 365–440, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 2005. View at Google Scholar
  22. F. C. Odds, “Synergy, antagonism, and what the chequerboard puts between them,” Journal of Antimicrobial Chemotherapy, vol. 52, no. 1, p. 1, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. National Committee for Clinical Laboratory Standards, Methods for Determining A Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A, National Committee for Clinical Laboratory Standards, Wayne, Pa, USA, 1999.
  24. S. K. Spangler, S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum, “Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and—negative bacteria,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 1, pp. 186–189, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Özbek and A. Şentürk, “Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii,” Chemotherapy, vol. 56, no. 6, pp. 466–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. Ç. Bozkurt-Güzel and A. A. Gerçeker, “Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients,” Journal of Antibiotics, vol. 65, no. 2, pp. 83–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Li, J. Turnidge, R. Milne, R. L. Nation, and K. Coulthard, “In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 3, pp. 781–785, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. R. J. Owen, J. Li, R. L. Nation, and D. Spelman, “In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 3, pp. 473–477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Ozbek and G. Otuk, “Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa,” Chemotherapy, vol. 55, no. 6, pp. 446–450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Gudmundsson, S. Einarsson, H. Erlendsdottir, J. Moffat, W. Bayer, and W. A. Craig, “The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model,” Journal of Antimicrobial Chemotherapy, vol. 31, pp. 177–191, 1993. View at Google Scholar · View at Scopus
  31. G. A. Pankuch and P. C. Appelbaum, “Postantibiotic effect of tigecycline against 14 gram-positive organisms,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 782–784, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Lefort, M. Lafaurie, L. Massias et al., “Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 1, pp. 216–222, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Stubbings, J. Bostock, E. Ingham, and I. Chopra, “Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 2, pp. 444–448, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Dubois and C. St-Pierre, “Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 4, pp. 41–46, 2000. View at Google Scholar · View at Scopus
  35. I. Odenholt-Tornqvist, “Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem,” Journal of Antimicrobial Chemotherapy, vol. 31, no. 6, pp. 881–892, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. D. N. Gilbert, “Once-daily aminoglycoside therapy,” Antimicrobial Agents and Chemotherapy, vol. 35, no. 3, pp. 399–405, 1991. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Prins, H. R. Buller, E. J. Kuijper, R. A. Tange, and P. Speelman, “Once versus thrice daily gentamicin in patients with serious infections,” The Lancet, vol. 341, no. 8841, pp. 335–339, 1993. View at Publisher · View at Google Scholar · View at Scopus
  38. C. D. Freeman, D. P. Nicolau, P. P. Belliveau, and C. H. Nightingale, “Once-daily dosing of aminoglycosides: review and recommendations for clinical practice,” Journal of Antimicrobial Chemotherapy, vol. 39, no. 6, pp. 677–686, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. D. S. Burgess, “Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance,” Chest, vol. 115, supplement 3, pp. 19–23, 1999. View at Google Scholar · View at Scopus
  40. G. L. Drusano, D. E. Johnson, M. Rosen, and H. C. Standiford, “Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 3, pp. 483–490, 1993. View at Publisher · View at Google Scholar · View at Scopus
  41. K. A. Rodvold and M. Neuhauser, “Pharmacokinetics and pharmacodynamics of fluoroquinolones,” Pharmacotherapy, vol. 21, no. 10, pp. 233S–252S, 2001. View at Google Scholar · View at Scopus
  42. P. Kardas, “Patient compliance with antibiotic treatment for respiratory tract infections,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 897–903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Tascini, E. Tagliaferri, T. Giani et al., “Synergistic activity of colistin plus rifampin against colistin-resistant kpc-producing Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 8, pp. 3990–3993, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Gerceker and G. Otuk, “Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa,” Chemotherapy, vol. 41, no. 6, pp. 433–436, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. I. M. Gould, A. C. Jason, and K. Milne, “Use of the malthus microbial growth analyser to study the post antibiotic effect of antibiotics,” Journal of Antimicrobial Chemotherapy, vol. 24, no. 4, pp. 523–531, 1989. View at Publisher · View at Google Scholar · View at Scopus